Toshiba to create more than 100 jobs in Edinburgh; Donovan steps down as Boston Sci's PR head;

> Toshiba Medical Visualisation Systems is to invest £15.5 million in a healthcare imaging programme in Edinburgh. It will create 26 jobs in the short-term and more than 100 within three years. Story

> Paul Donovan is abruptly out as Boston Scientific's PR chief, replaced by BSX newcomer Erik Kopp as director of communications. Report

> More than 90 jobs are to be lost in a medical equipment manufacturer in Tipperary while, separately, a further 50 positions are under threat in a Waterford chicken factory. In Tipperary town, 94 full-time and part-time jobs are to go after Pall announced it is to close its medical device manufacturing operations at the end of May. Article

> A heart attack strikes. A heart stops. It happened to Carl Honaker. Three months and several stents later, doctors say Carl could be implanted with a new heart attack warning system called the Guardian Alert System. Item

> Unilife has appointed Ramin Mojdeh, formerly VP and general manager of Becton Dickinson (BD) Pharmaceutical Systems, North America, and worldwide VP of R&D, BD Medical, as its new COO and executive VP, effective Feb. 7. Unilife release

> VisionCare Ophthalmic Technologies, a developer of advanced visual prosthetic devices for the treatment of end-stage age-related macular degeneration, today announced Elka Nir of Giza Venture Capital has joined VisionCare's board of directors. Nir expands the company's board to seven. VisionCare release

> Looking for a medical device job in 2011? You better bring expertise to the table, and maybe a passport, too. Story

And Finally... American Medical Systems won't be running an ad during Super Bowl XLV to tout its medical devices for impotence and incontinence. But the Minnetonka-based manufacturer rushed in the past few months to reach an agreement with the NFL Alumni Association to support a new health care program for pro-football retirees. News

Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.